<?xml version="1.0" encoding="iso-8859-1"?><rss version="2.0">
<channel>
<title>Novartis International AG</title>
<link>http://www.novartis.com</link>
<item>
<title>Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure</title>
<pubDate>2011-02-18T14:04:06 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1490537.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis appoints Naomi Kelman as new Head of the Novartis OTC division</title>
<pubDate>2011-02-17T07:00:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1489895.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis studies show Onbrez® Breezhaler® plus tiotropium provided greater increase in lung function than tiotropium alone</title>
<pubDate>2011-02-10T09:42:28 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1487540.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET, study published in NEJM shows </title>
<pubDate>2011-02-09T23:00:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1487280.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for use in children from 2 years of age</title>
<pubDate>2011-01-31T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1483545.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Innovation drives Novartis to double-digit growth for 2010</title>
<pubDate>2011-01-27T07:00:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia</title>
<pubDate>2011-01-24T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1481634.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis announces agreement to acquire Genoptix, Inc. in all cash offer</title>
<pubDate>2011-01-24T07:00:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1481651.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Novartis gains positive CHMP opinion for Gilenya®, first oral multiple sclerosis treatment recommended for approval in the European Union</title>
<pubDate>2011-01-21T13:00:09 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1481425.shtml</link>
<description><![CDATA[]]></description>
</item>
<item>
<title>Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab</title>
<pubDate>2011-01-10T07:15:00 CET</pubDate>
<link>http://www.novartis.com/newsroom/media-releases/en/2011/1478186.shtml</link>
<description><![CDATA[]]></description>
</item>
</channel>
</rss>

